SPV-400

SPV-400 is a novel small molecule tropomyosin receptor kinase B (TrkB) agonist under development by Spave Science for the treatment of neurological and nervous system disorders. It is designed to directly activate the TrkB receptor and downstream signaling pathways, thereby promoting neuroprotection and synaptic plasticity. By acting as a direct TrkB activator, SPV-400 aims to overcome the therapeutic limitations of brain-derived neurotrophic factor (BDNF), such as its short half-life, poor blood-brain barrier penetration, and systemic instability. Preclinical pharmacokinetic and ADME evaluations have demonstrated that SPV-400 has high aqueous solubility, limited interaction with cytochrome P450 enzymes, and favorable blood-brain barrier permeability, supporting its potential for further clinical development.